Cargando...
RDNA-10. HISTOPATHOLOGICAL AND GENOMIC CHARACTERIZATION OF GLIOBLASTOMA (GBM) RESECTED AFTER TUMOR TREATING FIELDS (TTFIELDS) THERAPY
BACKGROUND: TTFields are FDA-approved for treatment of newly-diagnosed and recurrent glioblastoma. In this study, GBMs from one patient pre- and post-TTFields monotherapy were analyzed by immunohistochemistry (IHC) and array comparative genomic hybridization (aCGH) to examine potential TTFields-indu...
Gardado en:
| Publicado en: | Neuro Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Oxford University Press
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6217519/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.925 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|